Wiseguyreports.Com Adds “Diabetes -Market Demand, Growth, Opportunities and Analysis of Top Key Player Forecast To 2022” To Its Research Database
The Indian diabetes market is estimated to grow with the CAGR of 20.5% during the period 2017-2022. The major factors that are augmenting the growth of the market are increase in the geriatric population of the India, urbanization and increasing prevalence of diabetes in the country. Additionally, rising obesity levels, innovation and development of new product for the diagnosis and treatment of diabetes and growing trend of the wearable devices and POC solution are also some of the major factors that are fuelling the growth of the Indian diabetes market.
India has huge potential for the growth of the diabetes market. Diabetes is an expensive and rapidly growing health problem all over the world. In 2015, it is estimated that the approximately 370 million across the globe have diabetes, out of which more than 90% of the population have Type-II diabetes. India has the second largest number of diabetic’s population in the world. In 2015, about 60 million people India is suffering from diabetes. Moreover, 75 million people are in the risk to develop diabetes. These are the major factors that are attracting multinational companies to invest in India. Therefore increasing investment by the key players in the India are driving the growth of the diabetes market.
Request for Sample Report @ https://www.wiseguyreports.com/sample-request/1509674-indian-diabetes-market-research-and-analysis-2015-2022
Increasing geriatric population is also one of the major factors driving the growth of the diabetes market in India. In the year 2015, population aging 65 year or older is estimated to account for about 6% of the total population of the India i.e. 78 million, it is further estimated to reach 8.8% by the year 2030. Population aging 65 or older are more prone to diabetes. Therefore increasing geriatric population in India is estimated to motivate the growth of the diabetes market in India.
However, there are certain factors that are affecting the growth of the diabetes market in India. Lack of awareness among people, high cost and recurring cost of treatment, lack of availability of insulin pumps and CGMS devices are some of the major constraints that are hindering the growth of the diabetes market in the region.
Key players of the Indian diabetes market are AstraZeneca Pharma India ltd, Eli Lily and company India ltd, GlaxoSmithKline Pharmaceuticals ltd, Glenmark Pharmaceuticals, Lupin pharmaceuticals ltd, Merck & co, Micro labs Ltd, MSD pharmaceuticals, Novartis India, Novo Nordisk India, Pfizer India, Sanofi Aventis, Sun Pharmaceuticals, USV India.
1. INDIAN DIABETES MARKET BY TYPE
2. INDIAN DIABETES MARKET BY DRUG CLASS
3. INDIAN DIABETES MARKET BY DEVICES
• Comprehensive research methodology of Global Indian Diabetes Market
• This report also includes detailed and extensive market overview with Analyst insights & key market trends.
• Exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
• Analysis of regional regulations and other government policies impacting the Global Indian Diabetes Market
• Insights about market determinants which are stimulating the Global Indian Diabetes Market
• Detailed and extensive market segments with regional distribution of forecasted revenues.
• Extensive profiles and recent developments of market players.
Table of Content
1. REPORT SUMMARY
1.1. RESEARCH METHODS AND TOOLS
1.2. MARKET BREAKDOWN
1.2.1. BY SEGMENTS
1.2.2. BY STAKEHOLDERS
2. MARKET OVERVIEW AND INSIGHTS
2.2. ANALYST INSIGHTS & CURRENT MARKET TRENDS
2.2.1. KEY FINDINGS
6. COMPANY PROFILES
7.1. ASTRAZENECA PHARMA INDIA LTD
7.1.2. ASTRAZENECA PHARMA INDIA LTD PRODUCT PORTFOLIO
7.1.3. ASTRAZENECA PHARMA INDIA LTD RECENT ACTIVITIES
7.2. ELI LILY AND COMPANY INDIA LTD
7.2.2. ELI LILY AND COMPANY INDIA LTD. PRODUCT PORTFOLIO
7.2.3. ELI LILY AND COMPANY INDIA LTD. RECENT ACTIVITIES
7.3. GLAXOSMITHKLINE PHARMACEUTICALS LTD
7.3.2. GLAXOSMITHKLINE PHARMACEUTICALS LTD PRODUCT PORTFOLIO
7.3.3. GLAXOSMITHKLINE PHARMACEUTICALS LTD RECENT ACTIVITIES
7.4. GLENMARK INDIA
7.4.2. GLENMARK INDIA PRODUCT PORTFOLIO
7.4.3. GLENMARK INDIA RECENT ACTIVITIES
7.5. LUPIN PHARMACEUTICALS LTD
7.5.2. LUPIN PHARMACEUTICALS LTD PRODUCT PORTFOLIO
7.5.3. LUPIN PHARMACEUTICALS LTD RECENT ACTIVITIES
7.6. MERCK & CO.
7.6.2. MERCK & CO. PRODUCT PORTFOLIO
7.6.3. MERCK & CO. RECENT ACTIVITIES
7.7. MICRO LABS LTD
7.7.2. MICRO LABS LTD PRODUCT PORTFOLIO
7.7.3. MICRO LABS LTD RECENT ACTIVITIES
7.8. MSD PHARMACEUTICALS
7.8.2. MSD PHARMACEUTICALS PRODUCT PORTFOLIO
7.8.3. MSD PHARMACEUTICALS RECENT ACTIVITIES
7.9.2. NOVARTIS PRODUCT PORTFOLIO
7.9.3. NOVARTIS RECENT ACTIVITIES
7.10. NOVO NORDISK INDIA
7.10.2. NOVO NORDISK INDIA PRODUCT PORTFOLIO
7.10.3. NOVO NORDISK INDIA RECENT ACTIVITIES
7.11. PFIZER INDIA
7.11.2. PFIZER INDIA PRODUCT PORTFOLIO
7.11.3. PFIZER INDIA RECENT ACTIVITIES
7.12. SANOFI INDIA
7.12.2. SANOFI INDIA PRODUCT PORTFOLIO
7.12.3. SANOFI INDIA RECENT ACTIVITIES
7.13. SUN PHARMACEUTICALS INDUSTRIES LTD
7.13.2. SUN PHARMACEUTICALS INDUSTRIES LTD PRODUCT PORTFOLIO
7.13.3. SUN PHARMACEUTICALS INDUSTRIES LTD RECENT ACTIVITIES
7.14. USV INDIA
7.14.2. USV INDIA PRODUCT PORTFOLIO
7.14.3. USV INDIA RECENT ACTIVITIES
Contact Us: Sales@Wiseguyreports.Com Ph: +1-646-845-9349 (Us) Ph: +44 208 133 9349 (Uk)